前列腺小细胞癌诊疗研究进展

孙奕飞; 张劲松; 李宁; 王海峰; 左毅刚; 王剑松

doi:10.13201/j.issn.1001-1420.2021.04.017

前列腺小细胞癌诊疗研究进展

- 昆明医科大学第二附属医院泌尿外科云南省泌尿外科研究所(昆明, 650101)
基金项目:
国家自然科学基金资助项目(No:81660423,81660422)

云南省科技厅-昆明医科大学联合基础研究面上项目(No:2017FE468-059)

详细信息

通讯作者: 张劲松,E-mail:zhangjinsongkm@163.com

中图分类号: R737.25

收稿日期: 2020-02-24

Research progress in diagnosis and treatment of small cell prostate cancer

- Department of Urology, Second Affiliated Hospital of Kunming Medical University, Yunnan Institute of Urology, Kunming, 650101, China

More Information

Corresponding author: ZHANG Jinsong, E-mail: zhangjinsongkm@163.com

Received Date: 24 February 2020

摘要

摘要: 前列腺小细胞癌(SCC)是前列腺癌的一种罕见的变体,也是最具侵袭性的恶性肿瘤之一。尽管有新一代AR途径抑制剂(阿比特龙、恩杂鲁胺)来治疗去势抵抗性前列腺癌,然而随着疾病进一步发展为神经内分泌性前列腺癌(NEPC)并严重影响患者预后,于是针对其最常见变体前列腺SCC的研究不断深入,但其发病机制及治疗手段等仍存在争议。本文以前列腺SCC患者为目标人群,总结其病理及临床特征,对发病机制、治疗方案的最新研究进展开展论述,以供后来更深入的研究。
- 前列腺肿瘤 /
- 小细胞癌 /
- 神经内分泌
Abstract: Prostate small cell carcinoma(SCC) is a rare variant of prostate cancer and one of the most aggressive malignancies. Although there is a new generation of AR pathway inhibitors(abiraterone, enzalutamide) to treat castration-resistant prostate cancer, the disease further develops to neuroendocrine prostate cancer(NEPC) and seriously affects the patient's prognosis. The research of SCC in the prostate is continuously deepened, but its pathogenesis and treatment methods are still controversial. In this paper, we take patients with prostate SCC as the target population, summarize their pathological and clinical characteristics, and discuss the latest research progress in pathogenesis and treatment options for further research in the future.
- prostate cancer /
- small cell carcinoma /
- neuroendocrine

HTML全文

参考文献(44)

[1]	Siegel RL,Miller KD,Jemal A.Cancer statistics,2020[J].CA Cancer J Clin,2020,70(1):7-30.
[2]	Furtado P,Lima MV,Nogueira C,et al.Review of small cell carcinomas of the prostate[J].Prostate Cancer,2011,2011:543272.
[3]	Wenk RE,Bhagavan BS,Levy R,et al.Ectopic ACTH,prostatic oat cell carcinoma,and marked hypernatremia[J].Cancer,1977,40(2):773-778.
[4]	Wang J,Liu X,Wang Y,et al.Current trend of worsening prognosis of prostate small cell carcinoma:A population-based study[J].Cancer Med,2019,8(15):6799-6806.
[5]	Deorah S,Rao MB,Ranman R,et al.Survival of patients with small cell carcinoma of the prostate during 1973-2003:a population-based study[J].BJU Int,2012,109(6):824-830.
[6]	Chen H,Sun Y,Wu C,et al.Pathogenesis of prostatic small cell carcinoma involves the inactivation of the P53 pathway[J].Endocr Relat Cancer,2012,19(3):321-331.
[7]	Li Z,Sun Y,Chen X,et al.p53 Mutation Directs AURKA Overexpression via miR-25 and FBXW7 in Prostatic Small Cell Neuroendocrine Carcinoma[J].Mol Cancer Res,2015,13(3):584-591.
[8]	Tan HL,Sood A,Rahimi HA,et al.Rb loss is characteristic of prostatic small cell neuroendocrine carcinoma[J].Clin Cancer Res,2014,20(4):890-903.
[9]	Tsai H,Morais CL,Alshalalfa M,et al.Cyclin D1 Loss Distinguishes Prostatic Small-Cell Carcinoma from Most Prostatic Adenocarcinomas[J].Clin Cancer Res,2015,21(24):5619-5629.
[10]	Lee JK,Phillips JW,Smith BA,et al.N-Myc Drives Neuroendocrine Prostate Cancer Initiated from Human Prostate Epithelial Cells[J].Cancer Cell,2016,29(4):536-547.
[11]	Dardenne E,Beltran H,Benelli M,et al.N-Myc Induces an EZH2-Mediated Transcriptional Program Driving Neuroendocrine Prostate Cancer[J].Cancer Cell,2016,30(4):563-577.
[12]	Guo CC,Dancer JY,Wang Y,et al.TMPRSS2-ERG gene fusion in small cell carcinoma of the prostate[J].Hum Pathol,2011,42(1):11-17.
[13]	Scheble VJ,Braun M,Beroukhim R,et al.ERG rearrangement is specific to prostate cancer and does not occur in any other common tumor[J].Mod Pathol,2010,23(8):1061-1067.
[14]	Wang X,Kruithof-de Julio M,Economides KD,et al.A luminal epithelial stem cell that is a cell of origin for prostate cancer[J].Nature,2009,461(7263):495-500.
[15]	Xin L.Cells of Origin for Prostate Cancer[J].Adv Exp Med Biol,2019,1210:67-86.
[16]	Goldstein AS,Huang J,Guo C,et al.Identification of a cell of origin for human prostate cancer[J].Science,2010,329(5991):568-571.
[17]	Sun Y,Niu J,Huang J.Neuroendocrine differentiation in prostate cancer[J].Am J Transl Res,2009,1(2):148-162.
[18]	Epstein JI,Amin MB,Beltran H,et al.Proposed morphologic classification of prostate cancer with neuroendocrine differentiation[J].Am J Surg Pathol,2014,38(6):756-767.
[19]	Parimi V,Goyal R,Poropatich K,et al.Neuroendocrine differentiation of prostate cancer:a review[J].Am J Clin Exp Urol,2014,2(4):273-285.
[20]	Zaffuto E,Pompe R,Zanaty M,et al.Contemporary Incidence and Cancer Control Outcomes of Primary Neuroendocrine Prostate Cancer:A SEER Database Analysis[J].Clin Genitourin Cancer,2017,15(5):e793-e800.
[21]	Guo A,Wen S,Ma Y,et al.Clinicopathological analysis on small cell carcinoma of the prostate in chinese patients[J].J Cancer,2014,5(9):797-803.
[22]	Yao JL,Madeb R,Bourne P,et al.Small cell carcinoma of the prostate:an immunohistochemical study[J].Am J Surg Pathol,2006,30(6):705-712.
[23]	忻志祥,迟辰斐,朱寅杰,等.神经内分泌前列腺癌20例临床病理特征及预后分析[J].临床泌尿外科杂志,2018,33(4):257-259,264.
[24]	Surcel CI,van Oort IM,Sooriakumaran P,et al.Prognostic effect of neuroendocrine differentiation in prostate cancer:A critical review[J].Urol Oncol,2015,33(6):265.e1-7.
[25]	赵园园,郗彦凤.前列腺原发小细胞神经内分泌癌10例临床病理分析[J].临床与实验病理学杂志,2019,35(12):1474-1476.
[26]	Huang YH,Zhang YQ,Huang JT.Neuroendocrine cells of prostate cancer:biologic functions and molecular mechanisms[J].Asian J Androl,2019,21(3):291-295.
[27]	Wang J,Wang FW.Impact of age on clinical presentation,treatment,and cancer-specific survival of patients with small-cell carcinoma of the prostate[J].Clin Interv Aging,2013,8:871-877.
[28]	Aggarwal R,Huang J,Alumkal JJ,et al.Clinical and Genomic Characterization of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer:A Multi-institutional Prospective Study[J].J Clin Oncol,2018,36(24):2492-2503.
[29]	Rueda-Camino JA,Losada-Vila B,De Ancos-Aracil CL,et al.Small cell carcinoma of the prostate presenting with Cushing Syndrome.A narrative review of an uncommon condition[J].Ann Med,2016,48(4):293-299.
[30]	Elston MS,Crawford VB,Swarbrick M,et al.Severe Cushing's syndrome due to small cell prostate carcinoma:a case and review of literature[J].Endocr Connect,2017,6(5):R80-R86.
[31]	Peverelli G,Grassi P.Pure small cell recurrent prostate cancer developing syndrome of inappropriate antidiuretic hormone secretion[J].Tumori,2017,103(Suppl 1):e56-e59.
[32]	潘立立,吴小艾,刁伟,等.正电子核素标记的前列腺特异性膜抗原小分子抑制剂在前列腺癌PET/CT中的研究进展[J].生物医学工程学杂志,2020,37(02):219-224.
[33]	Park JW,Lee JK,Witte ON,et al.FOXA2 is a sensitive and specific marker for small cell neuroendocrine carcinoma of the prostate[J].Mod Pathol,2017,30(9):1262-1272.
[34]	Xin Z,Zhang Y,Jiang Z,et al.Insulinoma-associated protein 1 is a novel sensitive and specific marker for small cell carcinoma of the prostate[J].Hum Pathol,2018,79:151-159.
[35]	Aparicio AM,Harzstark AL,Corn PG,et al.Platinum-based chemotherapy for variant castrate-resistant prostate cancer[J].Clin Cancer Res,2013,19(13):3621-3630.
[36]	Metzger AL,Abel S,Wegner RE,et al.Patterns of care and outcomes in small cell carcinoma of the prostate:A national cancer database analysis[J].Prostate,2019,79(12):1457-1461.
[37]	Malcolm J,Falzone N,Lee BQ,et al.Targeted Radionuclide Therapy:New Advances for Improvement of Patient Management and Response[J].Cancers(Basel),2019,11(2):268.
[38]	Hashimoto Y,Ishii Y,Kono S,et al.Intensity-modulated radiation therapy for small cell carcinoma of the prostate:A case report[J].Rep Pract Oncol Radiother,2017,22(5):349-353.
[39]	Beltran H,Oromendia C,Danila DC,et al.A Phase II Trial of the Aurora Kinase A Inhibitor Alisertib for Patients with Castration-resistant and Neuroendocrine Prostate Cancer:Efficacy and Biomarkers[J].Clin Cancer Res,2019,25(1):43-51.
[40]	Liu B,Li L,Yang G,et al.PARP Inhibition Suppresses GR-MYCN-CDK5-RB1-E2F1 Signaling and Neuroendocrine Differentiation in Castration-Resistant Prostate Cancer[J].Clin Cancer Res,2019,25(22):6839-6851.
[41]	Hofman MS,Violet J,Hicks RJ,et al.[(177) Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer(LuPSMA trial):a single-centre,single-arm,phase 2 study[J].Lancet Oncol,2018,19(6):825-833.
[42]	Puca L,Gavyert K,Sailer V,et al.Delta-like protein 3 expression and therapeutic targeting in neuroendocrine prostate cancer[J].Sci Transl Med,2019,11(484):eaav0891.
[43]	Pinato DJ,Vallipuram A,Evans JS,et al.Programmed cell death ligands expression drives immune tolerogenesis across the diverse subtypes of neuroendocrine tumours[J].Neuroendocrinology,2020.
[44]	Hansen AR,Massard C,Ott PA,et al.Pembrolizumab for advanced prostate adenocarcinoma:findings of the KEYNOTE-028 study[J].Ann Oncol,2018,29(8):1807-1813.